Grant will be used to advance the research and development of Soturi, a digital therapeutic (DTx) solution for Parkinson’s treatment.
Newel Health announced that it was selected to receive a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) [MJFF-022711] to advance the research and development of Soturi, a digital therapeutic (DTx) solution for personalized medication and treatment plan optimization for people with Parkinson’s disease.
Born from an investment play by Healthware Ventures and led by industry experts Gerry Chillè and PierPaolo Iagulli, Newel Health is a company that aims to improve healthcare for patients and doctors through the creation of beautifully designed and clinically validated digital medicine and digital therapeutic solutions. Built on a strong heritage in health innovation, Newel Health works in partnership with pharmaceutical companies, medical device manufacturers, and other health and wellness stakeholders.
According to the Soturi website, the Soturi app is intended for people living with Parkinson’s disease and may be suitable for patients 18 years or older who have been diagnosed with Parkinson’s disease at least 3 years ago. When first used, Soturi will ask questions to determine if it is right for the patient. The app and activity bracelet wearable work together to track symptoms, provide reminders, and guide the user through exercises.
“The Soturi app, developed in partnership with Orion Corporation, seeks to improve the lives of people living with Parkinson’s disease (PD) using data collected from a wearable sensor to determine how people are being impacted by PD in a free-living context,” says Gerry Chillè, chief strategy and innovation officer, Newel Health. “Soturi’s proprietary algorithms analyze the collected data to determine optimal treatment plan specific to the individual. It is an honor to have The Michael J. Fox Foundation fund our team’s innovative approach and the potential benefits that our digital solution can deliver to the PD community.”
PierPaolo Iagulli, chief operating officer, Newel Health, explains, “At Newel Health, we aim to create solutions like Soturi that can truly make a difference in people’s lives, by harnessing the power of data and technology and keeping the human touch at the forefront of our products. As we continue with this mission, H.Core, our proprietary software framework, propels us in accelerating the design, validation, production, and launch of all digital therapeutics and digital medicines.”
Caption: Smart phone screen showing Soturi app DTx solution for Parkinson’s patients. Image: Newel Health/Soturi